Glow Lifetech Valuation
Is GLOW undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GLOW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GLOW's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GLOW's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GLOW?
Key metric: As GLOW is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is GLOW's PS Ratio? | |
|---|---|
| PS Ratio | 19.4x |
| Sales | CA$344.75k |
| Market Cap | CA$6.68m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 22.5x |
| Enterprise Value/EBITDA | -7.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does GLOW's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16.2x | ||
AION Aion Therapeutic | 9x | n/a | CA$7.3m |
PWR Captiva Verde Wellness | 51.2x | n/a | CA$9.0m |
AUSA Australis Capital | 0.9x | n/a | CA$8.7m |
LOBE Lobe Sciences | 3.5x | n/a | CA$2.6m |
GLOW Glow Lifetech | 19.4x | n/a | CA$6.7m |
Price-To-Sales vs Peers: GLOW is good value based on its Price-To-Sales Ratio (19.4x) compared to the peer average (21.3x).
Price to Sales Ratio vs Industry
How does GLOW's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?
Price-To-Sales vs Industry: GLOW is expensive based on its Price-To-Sales Ratio (19.4x) compared to the Canadian Pharmaceuticals industry average (0.8x).
Price to Sales Ratio vs Fair Ratio
What is GLOW's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 19.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate GLOW's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Fennec Pharmaceuticals
US$129.5m
Operates as a biopharmaceutical company in the United States.
FRX
US$7.35
7D
30.1%
1Y
-38.9%
Verano Holdings
CA$765.1m
Operates as a vertically integrated multi-state cannabis operator in the United States.
VRNO
CA$2.02
7D
-14.8%
1Y
-65.2%
Decibel Cannabis
CA$28.8m
An integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada.
DB
CA$0.065
7D
0%
1Y
-53.6%